<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More


Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More


Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More


Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More


Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More


Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More


Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More


Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More


Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More


Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More


Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

Patient Tumors, PDX, and PDXO: Model Correlation Q&A

q&a on how to successfully develop PDX-derived organoids pdxo

q&a on how to successfully develop PDX-derived organoids pdxoAt our recent webinar we discussed our innovative PDX-derived organoid (PDXO) in vitro platform. We received many interesting questions on how these models correlate with their parental PDX and originating tumors, which we've summarized and had answered here by Dr. Rajendra Kumari, Global Head of Scientific Communication.

Tumor Microenvironment (TME)

What are the Tumor Microenvironment Physicochemical properties (pH, hypoxia) in PDXOs with Respect to Original Tumors?

Although organoids recapitulate tissue morphogenesis and pathophysiology of corresponding tissue in vivo, they are still an in vitro system. There may be some differences and specific culturing techniques may be devised to help mimic certain conditions.

Do PDOs maintain a TME in 3D Culture Similar to Parental Tumors?

PDO comparison to patient has been published by the Clevers lab and others. Here we show that PDXO derived from PDX models retain the histopathological features of the PDX.

Genetic Comparisons

At which Passage of your PDXO have you done your Genetic Comparison?

This varies as it is dependent on the time it takes to develop a robust stable organoid line which may be achieved over 3 passages or more.

Do you Clonally Select while Optimizing PDXO Culture Compared to PDX and the Patient?

This is a possibility although we haven’t investigated this against our PDX. We can say that we find close concordance when examining mutations and expression levels between PDXO and PDX.

The ~6% and ~3% of Differences in Gene Expression that you Report between PDXO and PDX, do you find that these are Consistently the Same Genes/Gene Families or is it Random?

This is a very interesting questions and something which we are currently looking into.

Pharmacological Response

How do you Correlate the Pharmacological Response of your PDXO with Patient Response?

We haven’t correlated PDXO response with patient response, our data correlate in vitro PDXO with in vivo PDX response.

Can you Explain why the Prediction Rate of PDX Response In Vivo is Worse for PDXO compared to the Prediction Rate of PDO to Patients?

The PDO prediction of the matched patient response was based on 21 matched datasets for about 5 different test agents for colorectal treatments. The PDXO correlation with in vivo PDX response is based on 32 matched sets (and this is a higher number now as more model data comes through) across 4 cancer types, 11 different models, and 12 different test agents.

Therefore, the depth and breadth of data is not the same, we are currently looking to dissect this out further into cancer types, therapeutic class, and mutational status.

You Mentioned that there was Poor Translation of Cetuximab from the PDXO to In Vivo PDX Models. Do you think this is Due to a Role of the Immune System e.g. ADCC or ADCP?

Yes, potentially and something we are looking into at the moment.

Check out our other posts to review more PDXO key questions around model development and utilities.

Related Posts